Access

Insight

Nature 446, 1000-1007 (26 April 2007) | doi:10.1038/nature05813; Published online 25 April 2007

Open Innovation Challenges

naturejobs

Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines

Danica P. Galonic acute1 & David Y. Gin2

Top

Therapeutic vaccines derived from carbohydrate antigen–adjuvant combinations are a promising approach for cancer immunotherapy. One of the critical limitations in this area is access to sufficient quantities of tumour-associated carbohydrate antigens and glycoconjugate adjuvants. At present, availability of the complex oligosaccharide constructs that are needed for the systematic design and evaluation of novel vaccine formulations relies on de novo chemical synthesis. The use of both state-of-the-art and emerging glycosylation technologies has led to significant advances in this field, allowing the clinical exploration of carbohydrate-based antigens in the treatment of cancer.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Chemical biology Dressed-up proteins

Nature News and Views (26 Apr 2007)